Objectives: In platelets, α-synuclein is important in calcium-dependent granule release. Notably, cells release α-synuclein in setting of cell damage or death. Therefore, we investigated α-synuclein levels in plasma of single donor platelet (SDP) units during storage.
| INTRODUC TI ON
α-Synuclein is part of a family of small proteins (14-17 kDa) that were first described in normal and malignant brain tissue. 1 In the central nervous system, although its function is not fully understood, it is expressed in both neuronal cytoplasm and in presynaptic terminals where it regulates neurotransmitter release, synaptic function, and neuronal plasticity. 2 Of interest, α-synuclein has been described as being in close proximity to all membranous structures in neurons.
However, under certain conditions structural changes leading to both α-synuclein oligomerization and fibrillary growth lead to one of the central pathologic findings of Parkinson's disease and other synucleinopathies.
2 α-Synuclein is also found in the hematopoietic system where it has been shown to be expressed in erythroid precursors and megakaryocytes in bone marrow, as well as erythrocytes and platelets in blood. 3, 4 Importantly, recent reports have shown that α-synuclein is essential to immunity as its absence leads to impairment in the late maturation stages of hematopoiesis, marked B cell and T cell lymphopoiesis, functional lymphocyte dysregulation, T helper (h)1 bias in setting of Th2 differentiation, impairment in immunoglobulin isotype-switching, and impaired adaptive immune responses.
5-7
In the megakaryocytic lineage, α-synuclein is expressed once megakaryocytes are fully mature and cease to express to β-synuclein which is only expressed early in megakaryoblastic development. 3 Along the same lines, α-synuclein has been shown to be a highly specific biomarker of neoplasms of the megakaryocytic cell lineage. 8 In platelets, α-synuclein is highly expressed and loosely associated with the plasma membrane, and it is in close association with membranous organelles and with secretory α-granules. 3 The function of α-synuclein in platelets is not known, but it appears to function as a negative regulator of calcium-dependent α-granule release. 9 This inhibitory function to keep platelets from degranulating seems to be closer to its biological function as exogenous α-synuclein inhibits von Willebrand factor release from endothelial cells upon stimulation. 10 Furthermore, α-synuclein deficiency leads to morphologically abnormal platelets in α-synuclein -/-mice. 5 In the United States, platelets are stored at room temperature (22-24°C) with continuous gentle agitation for a period of 5 days.
However, data from US centers which have extended units' shelf life to 7 days have not reported increases in adverse events secondary to transfusion. 11 Therefore, based on the aforementioned studies,
we set up to determine whether α-synuclein could be measured in platelet components during prolonged storage (7 days) and if changes in its concentration occur over time.
| MATERIAL S AND ME THODS

| Platelet units
Single donor platelet (SDP) samples were obtained from our local 
| α-Synuclein enzyme-linked immunosorbent assay (ELISA)
An ELISA kit containing a monoclonal antibody to the full length human α-synuclein protein was performed according to manufacturer's protocols (Invitrogen Co., Carlsbad, CA). Briefly, to quantify total α-synuclein concentration, purified recombinant α-synuclein at known concentrations was assayed in parallel to develop a standard concentration curve using serial protein dilutions to permit conversion of absorbance (optical density) into protein concentration. Samples were assayed at either 1: in the dark, stop solution was added, and plates were read at an absorbance of 450 nm using a model 680 microplate reader (Bio-Rad).
Recombinant α-synuclein standard was plotted with the absorbance (y-axis) against protein concentration (x-axis) to generate protein standard curve. α-synuclein concentration was determined using the concentration curve times the dilution factor.
| Flow cytometry of SDP
α-Synuclein expression was determined as previously described. Additionally, rabbit and mouse isotype controls were used during analyses (Abcam). Immunostaining was analyzed using FACSCanto II flow cytometer (BD Biosciences).
| Statistical analysis
Statistics were performed using Prism 6 (GraphPad Software Inc, La Jolla, CA) Results are presented as mean ± standard deviation (SD). All results were analyzed for statistical power, 13 and intergroup data comparisons were performed using one-way ANOVA and the Dunnett's multiple comparison tests. A P value of <0.05 was set for significance.
| RE SULTS
| α-Synuclein concentration in same SDP units followed for 7 days
In each experiment, a set of five SDP units were tested (three independent experiments using different SDP units, N = 15). Units on day of donation (day 0) had very low concentration of α-synuclein in the supernatant plasma concentration of 1.1 ± 0.8 ng/mL ( Figure 1A ). This is important as it is a concentration similar to that reported in plasma from normal subjects, 14 and it is within the limits of detection of the ELISA (1-100 ng/mL) as described by the manufacturer. By day 3, α-synuclein concentration began to increase when it reached a concentration of 11.7 ± 9.6 ng/mL (P = F I G U R E 1 A, Plasma α-synuclein concentration measured by ELISA in the same SDP units sampled on days 0, 3, 5, and 7. Significant increases in α-synuclein were seen at day 3 (*P = 0.025), day 5 (**P = 0.002) which reached highest levels on day 7 (***P < 0.0001) in comparison to day 0. Data are representative of three independent experiments on different set of five SDP units followed for the indicated time points. B, Plasma α-synuclein levels measured by ELISA in random SDP units sampled on days 0, 3, 5, and 7. Steady and continuous increase in α-synuclein was noted on day 5 ( ## P = 0.0047), which reaches highest levels on F I G U R E 2 Flow analysis of α-synuclein expression in platelets (y-axis represents counts). A, Isotype control, β-synuclein and γ-synuclein staining shows that platelets lack expression of these two synucleins as they did not differ from isotype control. B, Strong right shift in protein expression characterized staining with α-synuclein. Experiments analyzed a minimum of 100 000 events per sample and were similar in three independent experiments (N = 15)
| D ISCUSS I ON
We have previously reported the importance of α-synuclein in hematopoiesis and lymphopoiesis as shown by the lack of B cell maturation, isotype-switching in response to antigenic challenge, effacement of lymphoid organ architecture, T cell maturation deficiency, lymphocyte dysregulation of cytokine profile, anemia, and abnormal platelets. 5, 6 In relationship with the current findings, considering that platelets appear to be dependent on α-synuclein to regulate granular release, 9 increases in α-synuclein concentration in platelet units while in storage may indicate that this molecule can correspond to changes platelets undergo in a time-dependent manner during storage. These results were apparent regardless if the same units were sampled over time or when units were randomly tested. This is the first report indicating that α-synuclein can potentially be used to follow platelet units while in storage and may represent a biomarker of time-dependent cellular changes.
Looking closer at our results, we found at least one SDP unit in each experiment that on day of donation had no measurable α-synuclein. Interestingly, these same units by day 3 had levels of α-synuclein comparable to the other units from the same time point.
Furthermore, at least one unit on day 3 had larger increases of α-synuclein compared to the other units on that day but these units continued to increase α-synuclein on days 5 and 7 at comparable rates to the rest of the units of that time point so that by day 7 all units had similar α-synuclein concentration. It could be suggested that RBC contamination may be behind these increases based on a report that indicated RBCs contained most of the α-synuclein in blood. 15 However, this same report in its results and discussion revealed that their conclusions were based on the fact that there are more RBCs than other cell types in blood and in fact that by far the highest concentration of α-synuclein per milligram of cellular proteins is actually in platelets. 15 As all units used experimentally had hematocrits <2%. RBC contamination of a unit does not explain the outliers. Potentially, other factors during storage may have influenced this increase which was not seen during the rest of storage time measurements.
Despite over two decades of intense investigation in the central nervous system, the function of α-synuclein is still not well understood. However, current data indicate that its close interaction with neurotransmitter vesicles and with the transport system mediating their release imply that, at least under normal conditions, it is essential to axonal release of neurotransmitters. 1 While more research is needed to understand how α-synuclein mediates its function in hematopoiesis and lymphopoiesis, the close relationship of α-synuclein with membranes, and its ability to closely associate with soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes and promote their assembly 16 may provide clues to its function in the hematopoietic system and in lymphopoiesis.
Platelets contain both plasma/target membrane t-SNARE and vesicular/granular v-SNARE protein complexes which are essential to granule release. 17 Platelets' α-synuclein has been shown by electron microscopy to be closely associated with the plasma membrane, membranous organelles, and secretory granules. 3, 9 As this protein regulates α-granule release from platelets in a calcium-dependent manner, 9 these findings indicate that α-synuclein through its ability to mediate SNARE assembly may be essential to normal platelet responses.
Platelets are anucleated cellular structures which lack the ability to transcribe "de novo" RNA yet undergo an intrinsic apoptotic program that controls their survival and dictates their lifespan. 18 This preprogramming does not stop during their storage postcollection as they can also undergo apoptosis in vitro as they age. 19 Additionally, during processes of senescence and apoptosis, platelets release proteins and vesicles into plasma that reflect their biological decay. 20 These processes together with morphological changes, signs of activation/degranulation (CD62P, CD63 expression, release of β-thromboglobulin and platelet factor-4), proteolysis, and changes to surface receptor expression such as GPIb and GPIIb/IIIa are known as the platelet storage lesion. [21] [22] [23] As mentioned earlier α-synuclein mediates α-granule release, its concentration increases may be indicative of granular release and changes that platelets have undergone during storage.
α-Synuclein is also known to be immunogenic as in patients with
Parkinson's both T helper and T cytotoxic cells can readily recognize α-synuclein epitopes and mount strong reactions. 24 It is unclear, however, in light of our results whether these immune responses to α-synuclein would lead to immunogenicity in patients receiving platelet units closer to the end of their shelf life; nevertheless, this should be a matter of investigation to determine whether increasing amounts of α-synuclein in older platelet units lead to equivalent responses in their recipients.
In regard to pathogen reduction technology implementation which seeks to make the platelet inventory safer for recipients, it should be of interest that use of psoralen and ultraviolet A light therapy on platelets inhibits signal transduction and normal docking of liposomes onto α-synuclein. 25 These findings suggest that looking at α-synuclein concentration increases as a surrogate biomarker of changes to platelet biology in response to such technology may prove essential to determine if use of pathogen reduction leads to changes in platelets' health. Similarly, in light of the current increased interest in using cold-stored platelets, [26] [27] [28] it would also be of interest to establish whether α-synuclein concentration changes can also be indicative of platelet health in this setting as well. These areas should be investigated in the future studies.
In summary, α-synuclein is a protein that earned its reputation as an important biological mediator in the central nervous system, and structural dysregulation in its expression or assembly may be responsible for the pathology seen in synucleinopathies. α-synuclein is also important in hematopoiesis and changes to its concentration occur while platelets are in storage. Therefore, α-synuclein is not only an important mediator of hematopoiesis and lymphopoiesis but may also represent a biomarker for storage changes in platelets that will require further studies to gauge if concentration increases correlate with biochemical changes that occur during storage conditions. As the highest plasma concentrations of α-synuclein were observed on day 7, it remains to be elucidated the significance of these findings in platelets stored for this extended period. 
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